Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Chappuy

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Therapie|February 23, 2019
[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue<sup>®</sup>) in the prevention of opioid overdoses]Flavy Lenglard, Aurélie Berger-Vergiat, Delphine Ragonnet, et al.
Therapie|October 25, 2024
Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional studyAlice Deschenau, Benoit Trojak, Georges Brousse, et al.
Journal of Addictive Diseases|December 4, 2023
Patterns and determinants of cannabis use in youth visiting an urban emergency department in FranceRdah Touali, Mathieu Chappuy, Julia De Ternay, et al.
European Addiction Research|March 3, 2021
Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German Languages, among a Sample of Opioid UsersStéphanie Laconi, Raul Felipe Palma-Alvarez, Heino Stöver, et al.
Patient Preference and Adherence|June 24, 2021
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use DisorderMathieu Chappuy, Fadi Meroueh, Benoit Trojak, et al.
Drug and Alcohol Dependence|January 22, 2021
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadoneBenjamin Rolland, Benoit Trojak, Mikail Nourredine, et al.
L'Encephale|June 18, 2023
Screening problematic use of substances among young subjects attending an emergency department, and subsequent treatment seekingRdah Touali, Mathieu Chappuy, Aurélie Berger-Vergiat, et al.
Substance Use & Addiction Journal|May 14, 2026
Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal<sup>®</sup>) in France: A National Retrospective Cross-Sectional Study (OPALE 2)Alice Deschenau, Pascal Melin, Julien Azuar, et al.
Harm Reduction Journal|October 16, 2023
Willingness to use a drug consumption room among people who use drugs in Lyon, France, a city with no open scene of drug use (the TRABOUL survey)Mathieu Chappuy, Philippe Lack, Baptiste David, et al.
BMJ Open|October 13, 2025
Integrative exploration of bio-psycho-social determinants of DSM-5 severity levels of opioid use disorder: the BEBOP cohort study protocolLaurence Lalanne, Pierre-Eric Lutz, Alba Caparros-Roissard, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Therapie|February 23, 2019
[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue<sup>®</sup>) in the prevention of opioid overdoses]Flavy Lenglard, Aurélie Berger-Vergiat, Delphine Ragonnet, et al.
Therapie|October 25, 2024
Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional studyAlice Deschenau, Benoit Trojak, Georges Brousse, et al.
Journal of Addictive Diseases|December 4, 2023
Patterns and determinants of cannabis use in youth visiting an urban emergency department in FranceRdah Touali, Mathieu Chappuy, Julia De Ternay, et al.
European Addiction Research|March 3, 2021
Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German Languages, among a Sample of Opioid UsersStéphanie Laconi, Raul Felipe Palma-Alvarez, Heino Stöver, et al.
Patient Preference and Adherence|June 24, 2021
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use DisorderMathieu Chappuy, Fadi Meroueh, Benoit Trojak, et al.
Drug and Alcohol Dependence|January 22, 2021
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadoneBenjamin Rolland, Benoit Trojak, Mikail Nourredine, et al.
L'Encephale|June 18, 2023
Screening problematic use of substances among young subjects attending an emergency department, and subsequent treatment seekingRdah Touali, Mathieu Chappuy, Aurélie Berger-Vergiat, et al.
Substance Use & Addiction Journal|May 14, 2026
Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal<sup>®</sup>) in France: A National Retrospective Cross-Sectional Study (OPALE 2)Alice Deschenau, Pascal Melin, Julien Azuar, et al.
Harm Reduction Journal|October 16, 2023
Willingness to use a drug consumption room among people who use drugs in Lyon, France, a city with no open scene of drug use (the TRABOUL survey)Mathieu Chappuy, Philippe Lack, Baptiste David, et al.
BMJ Open|October 13, 2025
Integrative exploration of bio-psycho-social determinants of DSM-5 severity levels of opioid use disorder: the BEBOP cohort study protocolLaurence Lalanne, Pierre-Eric Lutz, Alba Caparros-Roissard, et al.
Pageof 2